The latest BSX stock forecast points to steady momentum, with analysts eyeing a potential upside toward the $68–$72 range over the next quarter. Boston Scientific continues to benefit from robust demand in cardiology devices, supported by Q1 revenue growth exceeding 14% year-over-year. Terms and Privacy Policy Your Privacy Choices CA Privacy Notice More Info Boston Scientific BSX has raised its full-year 2025 guidance following robust first-quarter results and continued momentum across key growth areas. The company now anticipates net sales to grow approximately 15-17% on a reported basis (earlier 12.5-14.5%) and nearly 12-14% on an organic basis (earlier 10-12%). Full-year adjusted earnings per share are expected to be in the range of $2.87-$2.94 (previously $2.80-$2.87). On the flip side, the company expects a $200 million tariff impact in 2025, mainly in the second half. The BSX stock forecast aligns with consistent dividend policy expectations, although Boston Scientific focuses more on reinvestment than high yield payouts.
